Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the current Good ...

Mumbai: Cipla started FY26 on a strong note with a 4 percent year-on-year (YoY) rise in income from operations at Rs 6,957 crore in Q1 FY26. Profit after tax (PAT) rose 10 percent YoY to Rs 1,298 ...

Cipla Ltd (BOM:500087) reports robust financial performance with significant milestones in India and strategic advancements in the US market.

Pharma Earnings: Cipla posts 10% rise in Q1 PAT to ₹1,298 crore, driven by growth in India, Africa, and Europe; revenue hits ₹6,957 crore.

Cipla's revenue from operations for the quarter ended June 30, 2025, increased by 3.9% year-on-year, reaching ₹6,957.47 crore. Other income also saw a significant rise of 61.4%, amounting to ...